Site icon Market Globalist

Sage Therapeutics Inc. [SAGE] gets an upgrade to a Buy from Guggenheim

SFT Stock

SFT Stock

Guggenheim took its Sage Therapeutics Inc. [NASDAQ:SAGE]‎‎ rating to the equivalent of Buy from ‎Neutral, ‎in a research note dated January 4, 2021. Other analysts also revised their coverage, with ‎Mizuho’s analysts upgrading the shares from “a ‎Neutral” rating to “a Buy” rating in a research note to ‎investors issued in early December. Meanwhile, ‎Raymond James had lowered its rating on SAGE to ‎‎”Mkt perform” from the earlier “an Outperform”, in ‎a research note produced for clients December ‎‎01, 2020. In addition, there was a downgrade from ‎Morgan Stanley on November 16, 2020. The rater ‎changed SAGE from “an Overweight” to “an Equal-‎weight”.

Get the ‎hottest stocks to trade every day before the market ‎opens 100% free. Click here ‎now. ‎‎

Is Sage Therapeutics Inc. [NASDAQ:SAGE] a Good Buy Right ‎Now?

It should be noted that ‎SAGE technical indicators for short, intermediate as well as long ‎term progress have placed an overall ‎average of 100% as Buy. The average signal changed from 100% ‎Buy in the last week and compares ‎with 88% Buy in the past month. Data from Sage Therapeutics Inc.’s ‎Trend Spotter indicated that the ‎signals were Weakest. The stock current average is 0.65 million shares ‎in the past 20 days and the short ‎term average signal indicates a 100% Buy. In the last 50 days, the ‎average trading volume was 0.72 ‎million shares while the medium term average advocated for 100% ‎Buy. The average long-term signal ‎stands at 100% Buy and the 100-day average volume stands at 0.7 ‎million shares.‎‎

Discover Tomorrow's Stocks Today!

When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.

Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored

SAGE Price Performance

On Wall Street, Sage Therapeutics Inc. ‎‎[NASDAQ:SAGE] finished ‎Thursday’s session down -2.42% at $86.51. The stock went up to $89.16 at the ‎same session while its ‎lowest single day price was $86.25. In the last five days, it saw a fall of about -‎‎2.45%, Sage Therapeutics ‎Inc. shares gained by almost 19.84% since the beginning of the year. ‎However, the share price has ‎dropped to as low as -4.49% below its one year high. On 12/28/20, the ‎company shares recorded ‎‎$90.58, the highest single-day price it has got to in the last 52-weeks and a ‎‎52-week low was seen on ‎‎03/18/20, the same year at $25.01. The company’s shares have inclined by ‎‎18.25% in the past year. The ‎‎50-day SMA achieved is $76.25 while the 200-day SMA is $52.54. Volume ‎dropped to 0.29 million from ‎‎0.34 million in the previous session.‎‎

SAGE Stock Support And ‎Resistance Levels

On the 24-hour scale, the immediate backing is ‎perceived around 85.45 level, ‎and in case of violation of this particular level, it will cause more drop to ‎‎84.40 level. On the upper level, ‎‎90.22 is still the key resistance. The stock may increase to the ‎subsequent resistance at 88.36. The ‎Relative Strength Index (RSI) pinned on the 14-day chart is 64.36, ‎implying a neutral technical stance ‎while the MACD stands at 5.70, meaning price will increase in the ‎next trading period. Percent R ‎indicator moved to 18.03%, implying bullish price movement. Stochastic ‎‎%K at 86.10% suggest selling ‎the stock.‎‎

What is the short interest in Sage Therapeutics Inc.?

Short interest in the Sage ‎Therapeutics ‎Inc. stock has surged, increasing by 40000.0 shares to total 5.31 million shares on Dec 14, ‎‎2020. The ‎interest had seen shares on Nov 12, 2020 stand at 5.35 million, data from Yahoo Finance ‎shows. The ‎decrease of -0.75% suggests the stock saw some decreased bullish sentiment. The stock’s ‎days to ‎cover (short ratio) moved to while the shorted shares account for just 14.10% of the overall ‎float for ‎the stock.‎‎

Sage Therapeutics Inc.’s Biggest Shareholders: Who Owns Sage Therapeutics ‎Inc. ‎‎[SAGE]?

Filings by Fidelity Management & Research Co showed that the firm now holds a ‎total of ‎‎7,732,540 shares or roughly 14.86% of the outstanding SAGE shares. This means their shares ‎have ‎increased by 8,468 from the 7,732,540 the investor reportedly held in its prior 13-F filing. With ‎the ‎conclusion of the purchase, The Vanguard Group, Inc. updated stake is worth $329,515,942. Details ‎in ‎the latest 13F filings reveal that T. Rowe Price Associates, Inc. disposed off their -9.22% stake valued ‎at ‎‎$189,598,829 while D. E. Shaw & Co. LP added theirs at $182,488,560. During the last quarter, T. ‎Rowe ‎Price Associates, Inc. liquidated -260,018 of its shares in Sage Therapeutics Inc. while D. E. Shaw ‎& Co. ‎LP bought 340,910 shares. The BlackRock Fund Advisors’s holdings currently number 2,372,497 ‎shares ‎at $205244715.47. According to the firm’s last 13F report, Great Point Partners LLC shares in ‎the ‎company at filing stood at 1,966,688 shares, roughly $145,711,914.‎‎

SAGE Earnings Forecast For ‎The Current Quarter

Sage Therapeutics Inc. [SAGE] is expected ‎to report strong earnings results ‎for the quarter ending on Dec 2020. Consensus estimates give the ‎company expected revenues of ‎‎$55.34M and an earnings per share of -$0.45 for Dec 2020. Looking ‎further ahead, the company is ‎expected to report revenue of $174.85M at an EPS of $0.91 for Mar ‎‎2021. The estimates represent ‎upside of 311.40% and 60.40% in the company’s revenue and earnings ‎per share, respectively, on a ‎year-on-year basis.‎‎

Get the hottest stocks to trade every day before the ‎market opens 100% ‎free. Click here now. 

SAGE Earnings Estimates For ‎The Current ‎Year

For the financial year, Sage Therapeutics Inc. [NASDAQ:SAGE] is expected to ‎bring in ‎revenue of $57.75M. The returns are nearly $50.88 million higher than the company’s actual ‎revenue ‎recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -7.39, higher ‎than that ‎of FY19 by $5.99. Estimates put this year’s earnings growth at 44.80%, 60.40% for the next, ‎and at an ‎annual 41.40% over the next 5-year period. As for sales, forecasts are for an increase of ‎‎740.90% in the ‎current fiscal year and a further 311.40% over the following year.‎